Chemoprophylaxis after oncological resections
Abstract
Background
National societies recommend extended-duration VTE chemoprophylaxis for up to 4 weeks following major oncologic resections with the literature demonstrating an incidence of approximately 2% for symptomatic VTE. Despite this, patients are not routinely discharged on VTE chemoprophylaxis at our institution.
Methods
A retrospective chart review was performed for major abdominal oncologic resections, including esophagectomy, at an academic community cancer center between 2016 and 2021. The primary outcome was the incidence of clinically evident VTE events (defined as lower extremity deep vein thrombosis (LE DVT) or pulmonary embolism (PE)) within 30 days of discharge and diagnosed on re-presentation. Exclusion criteria included in-hospital mortality, in-hospital VTE, or discharge on anti-coagulation. Comparisons were performed using Fisher’s Exact and Mann-Whitney test.
Results
After exclusion criteria were applied, 458 patients were identified. A total of 6 (1.3%) patients developed symptomatic VTEs, 5 (1.1%) PEs and 3 (0.7%) DVTs. No procedural interventions were required. On average, patients re-presented 14.3 (±8.4) days after discharge. There were no mortalities within 30 days of discharge. Intraoperatively, estimated blood loss in VTE group was decreased (150 vs 88 mL, p=0.01), while length of inpatient hospitalization (6.5 vs 10 days, p=0.05) was increased. Type of operation demonstrated an increased proportion of esophagectomy (9.6% vs 16.7%, p=0.57), palliative bypass (8.1% vs 33.3%, p=0.08) and small bowel resection (7.9% vs 33.3%, p=0.08) in the VTE group.
Conclusion
The percentage of symptomatic VTEs in our patients was not higher then reported averages despite no patient receiving chemoprophylaxis. Questions remain as to which subset of patients would benefit from chemoprophylaxis after major abdominal oncologic resection. Further investigation into long term effects of asymptomatic DVT should be undertaken.
Keywords
Full Text:
PDFReferences
References
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007 Mar;5(3):632-4.
Fagarasanu A, Alotaibi GS, Hrimiuc R, Lee AY, Wu C. Role of Extended Thromboprophylaxis After Abdominal and Pelvic Surgery in Cancer Patients: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2016 May;23(5):1422-30.
Gallus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost. 1997 Jul;78(1):126-32.
Kakkar AK, Haas S, Wolf H, Encke A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost. 2005 Oct;94(4):867-71.
Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):381S-453S.
Felder S, Rasmussen MS, King R, et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 2019 Aug 26;8(8):CD004318.
Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F, Valarani B, Bianchini C, Gussoni G. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006 Jan;243(1):89-95.
Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e227S-e277S.
Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020 Feb 10;38(5):496-520.
Anderson DR, Morgano GP, Bennett C, et al P. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-3944.
Merkow RP, Bilimoria KY, Sohn MW, Oh EH, Sellers MM, Paruch JL, Chung JW, Bentrem DJ. Adherence with postdischarge venous thromboembolism chemoprophylaxis recommendations after colorectal cancer surgery among elderly Medicare beneficiaries. Ann Surg. 2014 Jul;260(1):103-8.
Zipple M, Itenberg E. Improving adherence to recommended venous thromboembolic prophylaxis in abdominal and pelvic oncologic surgery. Surgery. 2018 Oct;164(4):900-904.
Mukkamala A, Montgomery JR, De Roo AC, Ogilvie JW Jr, Regenbogen SE. Population-Based Analysis of Adherence to Postdischarge Extended Venous Thromboembolism Prophylaxis After Colorectal Resection. Dis Colon Rectum. 2020 Jul;63(7):911-917.
Jørgensen LN, Lausen I, Rasmussen MS, Wille-Jørgensen P, Bergqvist D. Prolonged thromboprophylaxis with low-molecular weight heparin following major general surgery: an individual patient data meta-analysis. Blood. 2002; Vol. 100: abstract 1952 (poster).
Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002 Mar 28;346(13):975-80.
Jung YJ, Seo HS, Park CH, Jeon HM, Kim JI, Yim HW, Song KY. Venous Thromboembolism Incidence and Prophylaxis Use After Gastrectomy Among Korean Patients With Gastric Adenocarcinoma: The PROTECTOR Randomized Clinical Trial. JAMA Surg. 2018 Oct 1;153(10):939-946.
Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P; CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost. 2010 Jun;8(6):1223-9.
Sakon M, Kobayashi T, Shimazui T. Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study. Thromb Res. 2010 Mar;125(3):e65-70.
Lausen I, Jensen R, Jorgensen LN, et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg. 1998 Sep;164(9):657-63.
Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006 Nov;4(11):2384-90.
Vedovati MC, Becattini C, Rondelli F, et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg. 2014 Apr;259(4):665-9.
Klemen ND, Feingold PL, Hashimoto B. How Strong Is the Evidence Supporting Thromboprophylaxis in Surgical Oncology? J Clin Oncol. 2022 Feb 1;40(4):320-323.
Robinson KS, Anderson DR, Gross M, et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med. 1997 Sep 15;127(6):439-45.
Cohen AT, Bailey CS, Alikhan R, Cooper DJ. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty--a meta-analysis. Thromb Haemost. 2001 May;85(5):940-1.
Shimabukuro N, Mo M, Hashiyama N, Matsubara S, Nemoto H, Kobayashi Y, Masuda M. Clinical Course of Asymptomatic Isolated Distal Deep Vein Thrombosis of the Leg: A Single-Institution Study. Ann Vasc Dis. 2019 Dec 25;12(4):487-492. doi: 10.3400/avd.oa.19-00128. PMID: 31942206; PMCID: PMC6957892.
Engelke C, Rummeny EJ, Marten K. Pulmonary embolism at multi-detector row CT of chest: one-year survival of treated and untreated patients. Radiology. 2006 May;239(2):563-75.
Auer RC, Schulman AR, Tuorto S, et al. Use of helical CT is associated with an increased incidence of postoperative pulmonary emboli in cancer patients with no change in the number of fatal pulmonary emboli. J Am Coll Surg. 2009 May;208(5):871-8; discussion 878-80.
Bariteau A, Stewart LK, Emmett TW, Kline JA. Systematic Review and Meta-analysis of Outcomes of Patients With Subsegmental Pulmonary Embolism With and Without Anticoagulation Treatment. Acad Emerg Med. 2018 Jul;25(7):828-835.
Prasad V, Rho J, Cifu A. The diagnosis and treatment of pulmonary embolism: a metaphor for medicine in the evidence-based medicine era. Arch Intern Med. 2012 Jun 25;172(12):955-8.
Di Nisio M, Carrier M. Incidental venous thromboembolism: is anticoagulation indicated? Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):121-127.
Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):71-79.
Geahchan N, Basile M, Tohmeh M, registry D (2016) Venous thromboembolism prophylaxis in patients undergoing abdominal and pelvic cancer surgery: adherence and compliance to ACCP guidelines in DIONYS registry. Springerplus 5(1):1541. https://doi-org.ezproxylocal.library.nova.edu/10.1186/s40064-016-3057-9
Haac BE, Van Besien R, O'Hara NN, Slobogean GP, Manson TT, O'Toole RV, Johal H, Berger PZ, Reahl GB, Marinos D, Degani Y, Mascarenhas D, Connelly D, Scalea TM, Stein DM. Post-discharge adherence with venous thromboembolism prophylaxis after orthopedic trauma: Results from a randomized controlled trial of aspirin versus low molecular weight heparin. J Trauma Acute Care Surg. 2018 Apr;84(4):564-574. doi: 10.1097/TA.0000000000001771. PMID: 29251700.
Prien, C., Ribakow, D., Steele, S.R. et al. What About Patient Cost? Defining Copay and Out-of-Pocket Costs of Extended Venous Thromboembolism Chemoprophylaxis After Colorectal Surgery. J Gastrointest Surg 27, 152–154 (2023). https://doi-org.ezproxylocal.library.nova.edu/10.1007/s11605-022-05416-8
Cain K, Schmeler KM, Langley G et al. Patient cost associated with filling a prescription for extended-duration venous thromboembolism (VTE) prophylaxis following surgery for gynecologic cancer. Gynecol Oncol 2012; 127 (1): 18-21.
Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999 Sep;78(5):285-91.
Yoshida N, Baba Y, Miyamoto Y, et al. Prophylaxis of Postoperative Venous Thromboembolism Using Enoxaparin After Esophagectomy: A Prospective Observational Study of Effectiveness and Safety. Ann Surg Oncol. 2018 Aug;25(8):2434-2440.
van Es N, Di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017 Sep;102(9):1494-1501.
DOI: https://doi.org/10.23954/osj.v8i2.3463
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Open Science Journal (OSJ) is multidisciplinary Open Access journal. We accept scientifically rigorous research, regardless of novelty. OSJ broad scope provides a platform to publish original research in all areas of sciences, including interdisciplinary and replication studies as well as negative results.